Get the Stockscreener App
13.77
2.89%
-0.41
Indivior Plc stock is traded at $13.77, with a volume of 856.22K.
It is down -2.89% in the last 24 hours and up +21.43% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$14.18
Open:
$14.13
24h Volume:
856.22K
Relative Volume:
0.85
Market Cap:
$1.71B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
1,377.00
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
+0.58%
1M Performance:
+21.43%
6M Performance:
+16.20%
1Y Performance:
-15.73%
1-Day Range:
$13.70
$14.19
1-Week Range:
$13.48
$14.23
52-Week Range:
$7.33
$16.98
Indivior Plc Stock (INDV) Company Profile
Name
Indivior Plc
Sector
Phone
804-379-1090
Address
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
13.77 | 1.71B | 1.12B | 5.00M | -383.00M | 0.01 |
|
RGC
Regencell Bioscience Holdings Ltd
|
78.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
161.67 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
Indivior Plc Stock (INDV) Latest News
Indivior PLC Announces Changes in Major Holdings - TipRanks
Wirral Council v Indivior/Reckitt: Supreme Court refuses permission to appeal representative action strike out - stewartslaw.com
Indivior PLC Corrects Director Shareholding Disclosure - TipRanks
REGIndivior PLCDirector/PDMR ShareholdingCorrection - TradingView
Naloxone Market to Reflect Significant Incremental - openPR.com
Indivior Directors Increase Stake in Company Shares - TipRanks
Suboxone Market Set to Witness Growth as Opioid Dependency - openPR.com
Substance Abuse Treatment Market Size, Trends & Growth - openPR.com
Indivior PLC Announces Changes in Major Shareholdings - MSN
Indivior-Funded Study Suggests Opvee Outperforms Narcan. But at What? - Filter
INDV DEADLINE ALERT: Bernstein Liebhard LLP Reminds Indivior PLC Investors of Upcoming Deadline - ACCESS Newswire
Indivior PLC (INDV) Stock Analysis: Exploring a 9.21% Potential Upside Amidst Strategic Developments - DirectorsTalk Interviews
Suboxone Market Is Booming Nationwide with New Formulations - openPR.com
Shareholders that lost money on Indivior PLC(INDV) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Indivior PLC Announces Change in Major Shareholder Holdings - TipRanks
Levi & Korsinsky Notifies Shareholders of Indivior PLC(INDV) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference - GlobeNewswire Inc.
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq - MSN
Indivior PLC (INDV) Stock Analysis: Evaluating the 17.71% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Indivior PLC To Contact The Firm - ACCESS Newswire
Indivior’s exit comes as no surprise - The Times
Levi & Korsinsky Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming DeadlineINDV - ACCESS Newswire
Indivior PLC (INDV) Stock Price Down 3.27% on Jun 2 - GuruFocus
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Trending tickers: The latest investor updates on Tesla, Palantir, Sanofi, Babcock and Indivior - Yahoo
Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape - Kalkine Media
Indivior to delist from London Stock Exchangewill stay on Nasdaq - Insider Media Ltd
Drug maker Indivior joins London Stock Exchange exodus, 2 Jun 2025 11:00 - Shares Magazine
Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing - Kalkine Media
Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq - Kalkine Media
FTSE pharma giant joins London stock market exodus - The Telegraph
Indivior (INDV) Delists from London to Focus on U.S. Market - GuruFocus
Indivior brings curtain down on turbulent 11-year run in London - Proactive financial news
Indivior drops London listing to focus on U.S. market By Investing.com - Investing.com Nigeria
Indivior To Delist From LSE To Better Align With US Focused Business - Nasdaq
Indivior to cancel secondary listing in London - Sharecast.com
Indivior Plans to Cancel London Listing After Moving Primary to US - Bloomberg.com
Drug maker Indivior to abandon London stock market for the US - Yahoo
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - GuruFocus
Indivior to Cancel London Stock Exchange Listing, Focuses on Nasdaq - TipRanks
Indivior to Cancel Secondary Listing on London Stock Exchange, Maintains Primary Nasdaq Listing | Indivior Stock News - paginasiete.bo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing - marketscreener.com
Indivior Announces Intention to Cancel Secondary Listing on Lond - GuruFocus
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC LawsuitINDV - ACCESS Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer - The Malaysian Reserve
Indivior appoints Patrick Barry as Chief Commercial Officer By Investing.com - Investing.com South Africa
Indivior Announces Patrick Barry as Chief Commercial Officer | I - GuruFocus
Indivior appoints Patrick Barry as Chief Commercial Officer - Investing.com India
Indivior Announces Patrick Barry as Chief Commercial Officer | INDV Stock News - GuruFocus
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):